CME/CE
CME/CE CoursesYour search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME. |
Featured Courses
Virtual Patient: Comorbid Obesity in T2DM | myCME
1.00 CME CNE: To enhance your ability to treat patients with these 2 highly prevalent conditions, we invite you to participate in this interactive CME series via 3 interactive patient simulations. Exp 12/9/23
Practical Strategies for Probiotics in Neonatal Healthcare | myCME
0.75 CME: Experts provide an in-depth review of the most-recent evidence of the effectiveness, safety, and quality of probiotics in at-risk neonates. Exp 5/12/23
Understanding Lysosomal Storage Disorders | myCME
1.00 CME CE: General characteristics and clinical markers to aid recognition of Lysosomal Storage Disorders and key studies regarding therapy. Exp 12/6/23
Optimizing Treatment in Patients With HIV | myCME
0.75 CME: Covers evidence/guidelines for ART optimization in treatment-experienced patients with HIV and overview of emerging antiretrovirals. Exp 6/21/23
Maternal Alloimmunization and Hemolytic Disease of the Fetus and Newborn | myCME
1.50 CME CE: Interactive course discusses the pathogeneses of MA and HDFN, traditional management, and potential to integrate FcRn inhibitors. Exp 7/27/23
Advancing Therapy in Moderate-to-Severe Atopic Dermatitis | myCME
1.25 CME CE: This activity focuses on incorporating new therapies for the management of moderate-to-severe Atopic Dermatitis. Exp 6/30/23
The Impact of OSA-Related EDS on HRQoL | myCME
0.50 CME CE: Case 1 of 3-part series provides insight into the extensive impact of OSA-related EDS on psychosocial functioning and HRQoL. Exp. 5/11/23
Treatment Decisions for Patients with HCV and CKD | myCME
0.50 CME CE: This CMEO BriefCase will introduce a complex HCV case involving a patient with HCV and chronic kidney disease. Exp 5/17/23
Treatment Selection in a Patient with Decompensated Cirrhosis | myCME
0.50 CME CE: This CMEO BriefCase will introduce a case involving the incorporation of routine surveillance for HCC in a patient with HCV. Exp 5/17/23
Game-changers in Atopic Dermatitis and Alopecia Areata | myCME
2.00 CME CE: Provides education for advanced practice providers on the current and emerging therapies in atopic dermatitis and alopecia areata. Exp 6/1/23
Upstream Mediators With Next-Generation Biologics | myCME
0.75 CME: Provides clinicians with an understanding of the unmet needs in severe asthma, the alarmin pathway, and novel biologic therapies. Exp 7/29/23
Minimally Invasive Outpatient Procedures for BPH | myCME
1.25 CME CE: Three experts review strategies for identifying patients with BPH and clinical data on minimally invasive procedures. Exp 4/15/2023
More
Manifestations of Gaucher Disease: Rare or Under-recognized? | myCME
1.00 CME CE: Faculty discuss GD, including its less commonly reported manifestations, diagnostic pathways, and patient-centric multidisciplinary management of the disorder. Exp. 3/21/24
Improving Your OAB Care: A Focus on the Elderly and Male Patients | myCME
Identify LUTS in male patients that may represent BPH, OAB, or a combination of both. Discuss recent data on therapeutic options to manage OAB-wet and OAB-dry patients. Individualize the management of elderly patients with OAB, considering medication burden, comorbidities, and cognitive status.
Maintenance Therapy in the Long-Term Management of AML | myCME
1.50 CME CE: Live at ASH 2022, expert faculty discuss the use of maintenance therapy to improve long-term outcomes in AML and factors that contribute to disparities in care. Exp 1/23/24
The Patient Journey: Eliminating Disparities at Every Step | myCME
1.50 CME CE: In this CMEO webcast, expert faculty will discuss unconscious bias, racial and ethnic disparities, and health inequities. Exp. 12/22/23
Precision Medicine in Rheumatoid Arthritis | myCME
0.50 CME: In this presentation, HSS Physician-in-Chief Dr. Louis Bridges discusses precision medicine in the care of rheumatoid arthritis and why it is needed, the treatment efficacy and toxicity in rheumatoid arthritis database and repository (TETRAD) study, the Accelerating Medicines Partnership (AMP) program, and future directions. 11/8/2025
Rheumatoid Arthritis and the Mucosal Origins Hypothesis | myCME
0.75 CME: Hear from Dr. V. Michael Holers as he discusses the SERA study on the multiple factors that drive the initiation and development of seropositive rheumatoid arthritis, including genetic risk, environmental risk factors, and systemic autoimmunity. 11/8/2025
JAK Inhibitors for Rheumatoid Arthritis: Where Are We? | myCME
0.75 CME: Hear from Dr. Stanley Cohen as he provides a comprehensive overview of janus kinase (JAK) inhibitors and their development over the years, including several studies on their safety and efficacy and current guidelines. 11/8/2025
Unraveling the Molecular Underpinnings of Rheumatoid Arthritis Symptoms | myCME
0.50 CME: This presentation highlights current efforts in rheumatology to investigate and understand the molecular underpinnings of symptoms of rheumatoid arthritis (RA), particularly flares of RA, morning stiffness, and synovial inflammation and pain, as well as the relationship between these. 11/8/2025
Withdrawal and Tapering of Biologic Therapy in Rheumatoid Arthritis | myCME
0.50 CME: In this presentation, Dr. Allan Gibofsky aims to explore the question of whether patients who have achieved remission or low disease activity, can they be discontinued from biologics without increase in disease activity or progression of joint damage. 11/8/2025
Expanding the Scientific and Therapeutic Dimensions of Psoriatic Arthritis | myCME
0.75 CME: This presentation covers psoriatic arthritis, particularly mechanistic insights into the IL-23/IL-17 pathways, T resident memory cells, and the microbiome, prevention and combination strategies, including the PAMPA and Affinity trials, and diagnostic advances and new therapies. 11/8/2025
